Podcasts about tumours

Scientists at Dublin City University (DCU, Ireland), in collaboration with research teams in Chimie ParisTech – PSL (France), Chalmers University of Technology, Sahlgrenska University Hospital, Gothenburg (Sweden), and the University of Limerick (Ireland), have developed a new chemical strategy for designing metal-based compounds capable of damaging cancer cell DNA, offering a potential new direction for future anticancer drug development. Led by Professor Andrew Kellett, this European consortium has created a series of molecules that cut DNA through a distinct chemical mechanism compared with existing chemotherapy drugs. The research focuses on early-stage compounds that could form the basis of future therapies, particularly in cancers that become resistant to treatment. The scientists used click chemistry—a fast and reliable method for assembling molecular components—to create a family of compounds known as Tri-Click ligands. When combined with copper ions, these ligands form artificial metallo-nucleases, metal-containing agents designed to cleave DNA. Drug resistance remains one of the biggest challenges in cancer treatment. Tumours can adapt by repairing specific forms of DNA damage or by blocking the activity of conventional drugs. A key advantage of this new chemical strategy is that the compounds damage DNA via pathways that differ from those targeted by many current cancer treatments. This means they may avoid some of the typical mechanisms that cancers use to become resistant. Professor Andrew Kellett, Professor of Inorganic and Medicinal Chemistry at DCU, said: "Click chemistry has transformed how we build complex molecules, but its potential as a platform to assemble DNA-damaging chemotherapeutics is underexplored. One of the major challenges in cancer treatment is drug resistance. By developing compounds that damage DNA in a different way, we aim to open up new possibilities for overcoming some of the limitations of existing therapies. While this research is still at an early stage, it provides a valuable platform for future drug development." Professor Gilles Gasser, Professor of Bioinorganic Chemistry at Chimie ParisTech, said: "This work is clear evidence of the potential of metal-based compounds for anticancer research, going beyond the currently heavily used platinum-based drugs. While still in its infancy, this study is a first step towards new solutions for cancer treatment. On a completely different note, this work is another demonstration of the power of collaboration between European scientists and institutions." Professor Damien Thompson, Director of SSPC, the Research Ireland Centre for Pharmaceuticals & Professor of Molecular Modelling at UL, said: "This work exemplifies the value of systematic, deep screening of molecular properties in the development of more effective medicines. Support from SSPC, the Research Ireland Centre for Pharmaceuticals, enabled strong collaboration between our experimental and modelling teams, and this new design strategy marks a key milestone in developing sustainable, well-tolerated anticancer drugs." Professor Fredrik Westerlund, Professor of Molecular Bioscience at Chalmers University of Technology, said: "This study truly highlights how combined expertise across Europe can lead to innovative results in a research field of paramount importance. Novel treatments to resistant cancer tumours are highly desired in the clinics, and the metal compounds developed in this study have many of the properties that are eagerly sought for." The findings are published in the journal Nature Communications: https://www.nature.com/articles/s41467-026-68911-5 The researchers emphasise that the findings are preclinical, and further testing is required before any potential clinical application. More about Irish Tech News Irish Tech News are Ireland's No. 1 Online Tech Publication and often Ireland's No.1 Tech Podcast too. You can find hundreds of fantastic previous episodes and subscribe ...

A project at the cutting edge of cancer research hopes to build a collection of tiny lab-grown tumours at the University of Auckland. Smaller than a grain of sand, these tumour structures can be used to test experimental cancer treatments with quick results. Felix Walton has more.

Bowel cancer has traditionally been more common in older adults, but cases in people under 50 have been climbing sharply around the world. But now researchers in the UK are digging into one of the largest archives of preserved tumours to compare historic and modern cancers and analyse how they have changed over time. Joining Anton to discuss is Prof Kevin Monahan, consultant gastroenterologist at St Mark's Hospital in London.

TW: In this episode we discuss drug use, alcohol abuse, suicide and cancer. This week Reed sits down with the brilliant, brutally honest, and heart-meltingly funny Abi Feltham - the creator and influencer who talks openly about addiction, recovery, BPD, crack binges in Thailand, brain cancer, and somehow has you laughing through the tears. If you're flirting with sobriety, trying to hold on to it, or just feeling shaky as the festive season ramps up, this one is for you. Gentle, honest, raw, and full of “holy shit” wisdom. And if you want the ad-free video, plus our cosy December check-ins and community support, join us on Patreon. We love you. We're proud of you. And we're sober-curious with you. Rate & Review if this pod's ever made you laugh, cry, or rethink your bits — and support the show for extra juicy chats on Patreon: patreon.com/comecurious

Episode 335 Exercise has been shown to shrink tumours by 60 per cent. A new study shows another link between regular exercise and cancer prevention, this time revealing that muscle cells may outcompete cancer cells for energy - basically starving them. We explore the links between metabolism and glucose - with the caveat that so far this has only been demonstrated in mice, in a small study. The interstellar object 3I/ATLAS may be even weirder than we thought. Ever since we spotted this comet from another star system, scientists have been studying every inch of it. And no - it's not an alien spacecraft. But it does seem to be home to surprising amounts of chemicals like carbon dioxide and methanol - essential ingredients for life. Could this shed light on the origin of life in the universe? A 100-year-old debate between two titans of physics has finally been settled. In the 1920s, Albert Einstein and Niels Bohr butted heads about the nature of light. Einstein said light is a particle. Bohr said it's both a particle and a wave. They came up with an experiment to settle the argument - the trouble is, they had no way to run it. Now, 100 years later, we finally have the technology to perform the test - and the winner is… Hosted by Rowan Hooper and Penny Sarchet, with guests Alexandra Thompson, Alex Wilkins and Jacob Aron. To read more about these stories, visit https://www.newscientist.com/ Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode of PodMD, Head and Neck Surgeon, Surgical Oncologist and General Surgeon Dr Jingyi Cao will be discussing the topic of salivary gland tumours and stones. We discuss what salivary gland tumours and stones are, how they typically present, initial work up in general practice, their management, and more.

Across the world, scientists are still trying to answer one of medicine's most difficult questions: how can we safely and effectively treat brain cancers such as glioma? Despite decades of effort, outcomes for people diagnosed with high-grade glioma remain bleak. Current treatments, including surgery, radiotherapy, and chemotherapy, can slow the disease, but rarely stop it. The GlioLighT consortium, a multidisciplinary European research team funded by the European Innovation Council, has come together to explore a novel approach based on direct light therapy. Being in a very early stage, the project doesn't promise an immediate cure; instead, it sets out to answer a very fundamental question: can light itself trigger biological processes that might form the basis of a safe and targeted brain tumor therapy?

This National Brain Tumour Awareness Week, Brain Tumour Ireland is highlighting the symptoms of brain tumours in children and teenagers. Tumours of the brain and central nervous system are the most common childhood cancer, alongside leukaemia, but the symptoms can often be confused for other more common illnesses.Dr Sarah Curry, consultant neuro-oncologist at CHI Crumlin, and Cliona Leamy, mum to eight-year-old Izzy who was diagnosed with a brain tumour at the age of two, joined The Last Word to discuss the signs that can arise and the challenges some face in getting a diagnosis. Catch the full chat by pressing the 'Play' button on this page!

In today's episode, I'm joined once again by Dr. Steven A. Ross — historian, philosopher, and co-founder of the World Research Foundation. If you've ever explored his site lesscomplicated.net, you'll know it's a treasure trove of ancient wisdom, rare texts, and teachings that reach back thousands of years. We dive into a subject that has fascinated and divided people across cultures and centuries: miraculous, or what some call spontaneous, healing.   From documented medical records to historical accounts of healers who cured thousands through love alone, Dr. Ross brings forward examples that challenge the limits of what we think is possible. Our conversation explores the distinction between belief and faith, the ancient principle of 'know thyself,' and how love, laughter, and joy are not only emotional states but also catalysts for health.   We talk about the placebo effect, the power of expectation, and why the body — not medicine — is always the true healer. If you've ever wondered whether healing is simply mechanistic, or if there's a higher order of laws at play, this episode will invite you to reconsider the nature of health, faith, and the untapped capacities of the human spirit.   Feelings with Strangers Socials Insta: https://www.instagram.com/feelings.with.strangers/ YouTube: https://www.youtube.com/@FeelingswithStrangers   Cited Texts Tumours Melt Like Snowballs "Psychological Variables in Human Cancer," Journal of Prospective Techniques 31 (1957), pp. 331-40. The Modern Bethesda   Steven Ross Site: https://www.lesscomplicated.net/

In this episode, Michael and Josh continue to unpick the thorny question of germ-cell tumours, focusing this week on more advanced and relapsed disease. Germ cell tumours have an excellent prognosis, but unfortunately there are cases where more intense therapy is required. Listen on to find out about what to do when first line therapy is not enough!Studies discussed in this episodeBEP - Williams et al (1987)TIP - Gleeson et al (20224)For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

This episode is the first of a two-part mini-series where Michael and Josh attempt to untangle the complex topic of germ cell tumours, an area that requires specialist experience and a high-volume multi-disciplinary centre to treat adequately. Or, you could just listen to Oncology for the Inquisitive Mind and be a pro in no time!Studies discussed in this episodeEORTC-30982de Wit et al (2001)For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

“I'm not living the life I thought I would—but I *am* living. I'm no longer just existing. It's hard. It's painful. But it's real. This is my reality.”Nothing in my life feels "normal." There's no roadmap. Just the cards I've been dealt—and I'm learning to play them, even when the deck feels stacked against me.I've faced adversity that's shaped me into the person I am today. One moment that really stands out is being dismissed by a doctor when I raised concerns about breast cancer. That experience taught me a powerful lesson: "your gut is gold". You have to trust it—even when others won't listen.Key TakeawaysListen to your gut — It's there for a reason. Don't silence it to keep others comfortable.Take note of who shows up— When the sh*t hits the fan, you learn who's truly in your cornerBe your own advocate — Doctors are not gods. You know your body better than anyone."You do you” in health battles — There is no one-size-fits-all. Do what you need to survive, heal, or just make it through the day.Existing vs. Living — There's a world of difference. I've learned that choosing to "live"—even if it's messy or painful—is worth everything.allaboutyoupodcast@yahoo.comhttps://www.youtube.com/@allaboutyoupodcast2505

Changsong Qi joins Chloe Wilson and Ben Abbott of The Lancet to discuss their recently published phase 2 randomised controlled trial investigating Claudin-18 isoform 2-specific CAR T-cell therapy for previously treated advanced gastric or gastro-oesophageal junction cancer.Read the full article:https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00860-8/fulltext?dgcid=buzzsprout_icw_podcast_May_25_lancetContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

In this episode of the Onc Now Podcast, host Jonathan Sackier is joined by Joan Carles, Head of Section for the Genitourinary, Central Nervous System, Sarcomas and Tumours of Unknown Origin Unit at Vall d'Hebron University Hospital. Carles discusses breakthroughs in genitourinary cancer and sarcoma treatment, including anti-angiogenic therapies, overcoming resistance, and the role of genetic polymorphisms in personalised medicine.  Timestamps:     00:00 – Introduction   01:56 – Anti-angiogenic therapies  05:03 – Treatment resistance  07:53 – Genetic polymorphisms  09:02 – Sarcoma treatments  11:16 – Novel drugs  15:22 – Oncology societies  18:00 – Carles' three wishes for healthcare 

Talk 1: A/Prof Pratiti (Mimi) Bandopadhayay, Dana Farber Cancer Institute: Emerging precision oncology in brain tumoursTalk 2: Dr Frank Lin, UNSW: Integrating IT tools into trials of precision oncology

Andrew is joined by very special guest, neuroradiolgist Frank Gaillard, for a chat about posterior fossa tumours and his latest brain tumour course. Topics include ependymoma, choroid plexus papilloma,  medulloblastoma, pilocytic astrocytoma, haemangioblastoma and more!  Posterior Fossa Tumour Course ► https://radiopaedia.org/courses/posterior-fossa-tumours-learning-pathway Radiopaedia 2025 Virtual Conference ► https://radiopaedia.org/courses/radiopaedia-2025-virtual-conference Become a supporter ► https://radiopaedia.org/supporters Get an All-Access Pass ► https://radiopaedia.org/courses/all-access-course-pass Radiopaedia Community chat ► http://radiopaedia.org/chat Ideas and Feedback ► podcast@radiopaedia.org   The Reading Room is a radiology podcast intended primarily for radiologists, radiology registrars and residents. 

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/HKW865. CME credit will be available until January 31, 2026.Finding the Heat in Cold Tumours: Potential for Perioperative Immunotherapy Strategies in Early Breast Cancer In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/HKW865. CME credit will be available until January 31, 2026.Finding the Heat in Cold Tumours: Potential for Perioperative Immunotherapy Strategies in Early Breast Cancer In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/HKW865. CME credit will be available until January 31, 2026.Finding the Heat in Cold Tumours: Potential for Perioperative Immunotherapy Strategies in Early Breast Cancer In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/HKW865. CME credit will be available until January 31, 2026.Finding the Heat in Cold Tumours: Potential for Perioperative Immunotherapy Strategies in Early Breast Cancer In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/HKW865. CME credit will be available until January 31, 2026.Finding the Heat in Cold Tumours: Potential for Perioperative Immunotherapy Strategies in Early Breast Cancer In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/HKW865. CME credit will be available until January 31, 2026.Finding the Heat in Cold Tumours: Potential for Perioperative Immunotherapy Strategies in Early Breast Cancer In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/HKW865. CME credit will be available until January 31, 2026.Finding the Heat in Cold Tumours: Potential for Perioperative Immunotherapy Strategies in Early Breast Cancer In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/HKW865. CME credit will be available until January 31, 2026.Finding the Heat in Cold Tumours: Potential for Perioperative Immunotherapy Strategies in Early Breast Cancer In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.

I am joined in this podcast by Christine Miskelly to discuss her experience of witnessing how a brain tumour manifested in her husband Ivor. Christine narrated the subtle symptoms that Ivor first manifested, such as poor planning, social withdrawal, excessive slowness, impassivity and easy distractibility. We also discussed how the brain tumour altered Ivor's personality, particularly reducing his empathy, and how it impacted on their relationship. The podcast also explores the shock of getting a brain tumour diagnosis for Ivor, but also how this brought them together to face the challenges ahead. We also discussed the brain biopsy and the treatment plan which included surgery and radiotherapy. Our conversation also explored Ivor's sad progression, his post-treatment initial improvement before the subsequent progression as he developed seizures, and as his scan showed further tumour growth. Christine explored the emotional turmoil she went through this period, and how family, friends, and the kindness of strangers helped her to cope. Her perspectives also included how the whole experience included finding beauty and love. Other themes we covered were Ivor's advance directive, his terminal decline in a care home, and the aftermath of his death. Christine did her first degree in Psychology at the University of Durham back in the 1970s, and the bulk of her career was spent teaching Psychology at A-level. In more recent years, she studied Consciousness and Transpersonal Psychology with the Alef Trust. She said supporting students through this period of their lives has been one of her great joys.

In this podcast I explore the diverse perspectives of brain tumours, from their pathology and clinical manifestations to their complications and management. The podcast discusses the common primary brain tumours, particularly highlighting the usually benign meningioma, and the typically aggressive glioblastoma. I illustrate these themes with such graphic illness memoirs as The Iceberg by Marion Coutts, All in My Head by Jessica Norris, and Difficult Gifts by Courtney Burnett. I also discussed secondary brain tumours using the illustrative memoir of Barbara Lipska titled The Neuroscientist Who Lost Her Mind. These memoirs helped to demonstrate the sinister and the subtle symptoms of brain tumours, their investigations, and their treatments – chemotherapy, radiotherapy and surgery. This theme also explored the risk factors for brain tumours, and their investigational treatments. I also explored the fascinating history of brain tumour surgery which chronicled the contributions of such pioneering neurosurgeons as William McEwan, Rickman Godlee and Victor Horsley, and I cited such accounts as that of Andrew Wickens titled A History of the Brain, and that of Michael Aminoff titled Victor Horsley.

From the elusive neuroendocrine tumours like Rathke's Cleft Cysts and pituitary gland tumours to the broader impacts these conditions have on daily life, we explore it all. Join us as we navigate through the complexities of the body's inner workings, discuss the latest medical research, and hear firsthand accounts from those on the front lines of their own medical journeys. Whether you're a medical professional, a patient, or simply curious about the oddities of human biology, The Mutation Station offers insights and inspiration for everyone. Tune in to discover more about the mysteries of the human body and the resilience of the human spirit.

Maurie Markman, MD - Testing Impacts Treatment: Applying Best Practices in HER2 Assessment in Solid Tumours

Maurie Markman, MD - Testing Impacts Treatment: Applying Best Practices in HER2 Assessment in Solid Tumours

Maurie Markman, MD - Testing Impacts Treatment: Applying Best Practices in HER2 Assessment in Solid Tumours

Simron Singh, MD, MPH - Addressing the Challenges of Treating Highly Proliferative Neuroendocrine Tumours: Review of the Latest Evidence

Simron Singh, MD, MPH - Addressing the Challenges of Treating Highly Proliferative Neuroendocrine Tumours: Review of the Latest Evidence

Ravi Ramjeesingh, MD, PhD, FRCPC - Immunotherapy for Biliary Tract Cancers: Changing the Narrative in Rare and Aggressive Tumours

Astrocytes are cells in the central nervous system crucial for supporting neurones and their function. A glioblastoma is a dangerous, rapidly growing type of brain tumour. Guess how they are linked.  

Have you ever heard of a genetic condition called neurofibromatosis, also known as NF?It's one of the most common genetic disorders, affecting about 1 in 3000 people globally. NF causes different types of tumours to form in various parts of the body. Because so little is known about the condition, it's often misdiagnosed, or not diagnosed at all. UHN is home to the Elisabeth Raab Neurofibromatosis Clinic, the only adult NF clinic in Canada. We discuss the clinic and the exciting research happening in the field of NF. But, for many people living with the condition, the stigma is often as challenging as the illness. Featuring: Dr. Suganth Suppiah – Surgeon-scientist at UHN's Krembil Brain Institute and Assistant Professor at the University of Toronto. Dr. Suppiah also leads the nerve surgery program at the Elisabeth Raab Neurofibromatosis Clinic, Canada's only adult NF clinic, based at UHN.Dr. Ryan Thomas – Family physician and Clinical Associate who works with patients at the Elisabeth Raab Neurofibromatosis Clinic. Dr. Thomas lives with neurofibromatosis himself.Additional resources: Canadian first: UHN Opens Multidisciplinary Clinic on Genetic DisorderElisabeth Raab Accelerator of Science to End NeurofibromatosisNeurofibromatosis Ontario Dr. Gelareh Zadeh's lab – link to more info about the Elisabeth Raab Neurofibromatosis ClinicChildren's Tumour FoundationThe Your Complex Brain production team is Heather Sherman, Jessica Schmidt, Dr. Amy Ma, Kim Perry, Sara Yuan, Meagan Anderi, Liz Chapman, and Lorna Gilfedder.The Krembil Brain Institute, part of University Health Network, in Toronto, is home to one of the world's largest and most comprehensive teams of physicians and scientists uniquely working hand-in-hand to prevent and confront problems of the brain and spine, such as Parkinson's, Alzheimer's, epilepsy, stroke, spinal cord injury, chronic pain, brain cancer or concussion, in their lifetime. Through state-of-the-art patient care and advanced research, we are working relentlessly toward finding new treatments and cures.Do you want to know more about the Krembil Brain Institute at UHN? Visit us at: uhn.ca/krembilTo get in touch, email us at krembil@uhn.ca or message us on social media:Instagram - @krembilresearchTwitter - @KBI_UHNFacebook - https://www.facebook.com/KrembilBrainInstituteThanks for listening!

Bryan Choi - Assistant Professor of Neurosurgery at Harvard Medical School and Associate Director of the Centre for Brain Tumour Immunology and Immunotherapy at Mass General (Massachusetts General Hospital)

Andy Tudor thought be might be getting early onset dementia or having a stroke when he was eventually admitted to hospital. When he was told he had a huge 7cm tumour in his brain it was almost a relief, he tells Elizabeth and Julia in this episode released during Brain Tumour awareness month. Seven years ago Andy had life-saving neurosurgery to remove the growth. He is beating the statistics which show just 12% of adults diagnosed with a brain tumour survive after five years. Andy has since gone on to have an active role in raising awareness of brain tumours through volunteering and as the co-host of Let's Talk about Brain Tumours - a podcast run by the Brain Tumour Charity. Andy tells Elizabeth and Julia how his life feels more fulfilling now than before his brain injury but the worry of regrowth is always there and two years ago he had to have radiation when some was found on a routine scan. Andy talks about some of the symptoms he experienced and reveals some of his strategies for dealing with fatigue, one of which includes a can of baked beans! Listen to find out more. In this episode you will learn: Some of the key symptoms of a brain tumour in adults and children How humour can help in tough times Finding new purpose in life after brain injury Ways to deal with the process of grieving your old self and embracing new after brain trauma. Strategies for dealing with neuro-fatigue. Why a supportive family can help life you up and give you hope. Andy is the co-host of Let's Talk About Brain Tumours - run with the Brain Tumour Charity Connect with Andy on X @Meningioma_host You can listen to the episode we did with Andy and Sarah for Let's Talk About Brain Tumours, Life After Brain Injury On A Good Day Thank you for listening to On A Good Day! Please go back and catch up on any missed episodes. For a full recap of Elizabeth and Julia's stories, listen to episode #1: How Brain Injury Came Into Our Lives - And Changed Them Forever. Please share this podcast with others it will benefit and subscribe, rate and review to help make it more visible! We'd be so grateful! Connect with Us On Instagram @onagood.day and X (formally Twitter) @onagood_day And you can join our Facebook community too! Learn more about your ad choices. Visit megaphone.fm/adchoices

According to Cancer Australia's latest data, over 1,900 Australians received a diagnosis of brain cancer in 2023, positioning it as the ninth most prevalent cause of cancer-related fatalities in the country. In this podcast, Dr Bhaumik Shah, an oncologist in Melbourne, discusses brain tumours and cancer, addressing symptoms and available resources to aid those affected by this condition.

Paul Wheatley-Price, MBChB, MD - The Track to Better Outcomes: Identifying and Managing Patients With NTRK-Positive Solid Tumours

David McDermott discusses melanoma and renal data. We never get to bladder or lung.

This episode covers brain tumours.Written notes can be found at https://zerotofinals.com/medicine/neurology/braintumours/ or in the neurology section of the 2nd edition of the Zero to Finals medicine book.The audio in the episode was expertly edited by Harry Watchman.

Join Professor Michael Solomon, Dr Kilian Brown and Dr Jacob Waller from Royal Prince Alfred Hospital in Sydney, Australia, for this special four part series on pelvic exenteration surgery for locally advanced and recurrent rectal cancer. Learn about these ultra-radical procedures which go beyond the traditional TME planes that we learn during surgical training, and into all compartments of the pelvis. Episode 3 outlines the radical technical approaches to posterior and laterally invasive tumours, including en bloc iliac vascular resection and reconstruction, as well as radical sacrectomy techniques. Each episode in this series features a different international guest surgeon. In episode 3, the RPA team are joined by Dr Oliver Peacock from the University of Texas MD Anderson Cancer Centre, USA. Technical descriptions and videos: Shaikh I, Holloway I, Aston W, Littler S, Burling D, Antoniou A, Jenkins JT; Complex Cancer Clinic St Mark's Hospital London. High subcortical sacrectomy: a novel approach to facilitate complete resection of locally advanced and recurrent rectal cancer with high (S1-S2) sacral extension. Colorectal Dis. 2016 Apr;18(4):386-92. doi: 10.1111/codi.13226. PMID: 26638828. https://pubmed.ncbi.nlm.nih.gov/26638828/ Brown KGM, Solomon MJ, Austin KKS, Lee PJ, Stalley P. Posterior high sacral segmental disconnection prior to anterior en bloc exenteration for recurrent rectal cancer. Tech Coloproctol. 2016 Jun;20(6):401-404. doi: 10.1007/s10151-016-1456-0. Epub 2016 Mar 21. PMID: 27000857. https://pubmed.ncbi.nlm.nih.gov/27000857/ Sutton PA, Solomon M, Sasidharan P, Lee P, Austin K. Abdominolithotomy sacrectomy for the management of locally recurrent rectal cancer: video vignette. Br J Surg. 2021 Aug 19;108(8):e257. doi: 10.1093/bjs/znab105. PMID: 34089593. https://pubmed.ncbi.nlm.nih.gov/34089593/ Drami I, Fletcher JA, Corr A, West MA, Aston W, Hellawell G, Burns EM, Jenkins JT. Total pelvic exenteration with 'high and wide' sacrectomy for recurrent rectal cancer: A video vignette. Colorectal Dis. 2022 Dec;24(12):1625-1626. doi: 10.1111/codi.16230. Epub 2022 Jul 18. PMID: 35730692. https://pubmed.ncbi.nlm.nih.gov/35730692/ References: Rajendran S, Brown KGM, Solomon MJ. Oncovascular surgery for advanced pelvic malignancy. Br J Surg. 2023 Jan 10;110(2):144-149. doi: 10.1093/bjs/znac414. PMID: 36427187. https://pubmed.ncbi.nlm.nih.gov/36427187/ Austin KK, Solomon MJ. Pelvic exenteration with en bloc iliac vessel resection for lateral pelvic wall involvement. Dis Colon Rectum. 2009 Jul;52(7):1223-33. doi: 10.1007/DCR.0b013e3181a73f48. PMID: 19571697. https://pubmed.ncbi.nlm.nih.gov/19571697/ Rogers AC, Jenkins JT, Rasheed S, Malietzis G, Burns EM, Kontovounisios C, Tekkis PP. Towards Standardisation of Technique for En Bloc Sacrectomy for Locally Advanced and Recurrent Rectal Cancer. J Clin Med. 2021 Oct 25;10(21):4921. doi: 10.3390/jcm10214921. PMID: 34768442; PMCID: PMC8584798. https://pubmed.ncbi.nlm.nih.gov/34768442/ van Kessel CS, Waller J, Steffens D, Lee PJ, Austin KKS, Stalley PD, Solomon MJ. Improving Surgical Outcomes in Pelvic Exenteration Surgery: Comparison of Prone Sacrectomy with Anterior Cortical Sacrectomy Techniques. Ann Surg. 2023 Jul 24. doi: 10.1097/SLA.0000000000006040. Epub ahead of print. PMID: 37485983. https://pubmed.ncbi.nlm.nih.gov/37485983/  ***Fellowship Application - https://forms.gle/5fbYJ1JXv3ijpgCq9*** Please visit https://app.behindtheknife.org/home to access other high-yield surgical education podcasts, videos and more.  If you liked this episode, check out our recent episodes here https://app.behindtheknife.org/listen

This episode is hosted by Thomas Slavin, MD, FACMG, DABMD, a Chief Scientific Officer at HALO Precision Diagnostics  and features Laura Valle, PhD, a Principal Investigator, at the Catalan Institute of Oncology, IDIBELL. They discuss the position statement on the APC I1307K allele and its association with cancer predisposition which was generated by a multidisciplinary international expert group endorsed by the International Society for Gastrointestinal Hereditary Tumours (InSiGHT). Read our blog post "Evidence based guidance for APC I1307K and Cancer Risk" hereStay tuned for more podcasts in 2024! If you missed any of our earlier 2023 podcasts, you can find them here

Many of the guests on this podcast have emphasized the importance of awareness. Awareness of how we think can help improve how we think. Awareness of implicit bias can improve how we implement our true values. Awareness of emotions can improve how we react or don't react to different situations. I find awareness difficult to cultivate, and I have always admired Dr. Earl Glusac's ability to be present, calm, and steady. Dr. Glusac has been meditating regularly since 2005 (as well as when he was younger), and he shares his view on meditation as well as tips for a productive career in academic medicine. Dr. Earl J. Glusac, MD is a distinguished dermatopathologist and esteemed professor at Yale University School of Medicine. He has actively shaped the field through his roles on various medical board. He has served the American Boards of Pathology and Dermatology and the editorial boards of the Journal of Cutaneous Pathology and the American Journal of Dermatopathology; he was program director and president of the American Society of Dermatopathology, and he is an author for the World Health Organization's Classification of Tumours of the Skin. He attended Michigan State University for his medical degree, spent time in California for his residency training as well as dermatopathology fellowship, and has spent the majority of his dermatopathology career at Yale. Much of his research relates to the problem of overdiagnosis, especially as related to benign lesions that mimic malignant melanoma. 

Another quick bonus episode, this time to launch Frank's new enhancing brain tumours neuroradiology course - part 2 of his magnum opus. HALF PRICE this month (just $20) and free for All-Access Pass holders. A guided tour through 7 scrollable cases and 6 practice cases with related discussion and articles.  Enhancing Brain Tumours Course ► https://radiopaedia.org/courses/enhancing-brain-tumours-learning-pathway Become a supporter ► https://radiopaedia.org/supporters Get an All-Access Pass ► https://radiopaedia.org/courses/all-access-course-pass Andrew's Twitter ► https://twitter.com/drandrewdixon Frank's Twitter ► https://twitter.com/frankgaillard Ideas and Feedback ► podcast@radiopaedia.org   The Reading Room is a radiology podcast intended primarily for radiologists, radiology registrars and residents. 

Maori are disproportionately affected by brain tumours. Dr Thomas Park  using AI to scan a huge library of tumours collected from Maori and Pasifika patients to understand why.

How did the Ark of the Covenant end up in a cart with golden mice and tumours pulled by complaining milch cows? Well, there's quite a story there! Based on 1 Samuel 5:1-7:1. Show notes have been posted at retellingthebible.wordpress.com.   Media in this Episode The following music was used for this media project: Music: AhDah by Kevin MacLeod Free download: https://filmmusic.io/song/3345-ahdah License (CC BY 4.0): https://filmmusic.io/standard-license Artist website: https://incompetech.com Music: River of Io by Kevin MacLeod Free download: https://filmmusic.io/song/4296-river-of-io License (CC BY 4.0): https://filmmusic.io/standard-license Support Retelling the Bible If you would like to support the work that I do creating these stories, go to patreon.com/retellingthebible and choose a level of support!

With Christian Kollmannsberger

This week we've found ourselves attracted by the topic of magnetism; it's what makes it possible to generate and distribute electricity to our homes, or send messages and radio broadcasts over the airwaves; it underpins our ability to see inside the body with technologies like MRI scanners, and thanks to the fact that there's a massive magnetic field surrounding our planet, much of the radiation onslaught from space that would otherwise hit us is fended off, keeping the Earth habitable. That planetary magnetic field also provides us and animals with a way to navigate, and there are even... Like this podcast? Please help us by supporting the Naked Scientists

Cold exposure in mice activates brown fat to deny tumours glucose, and the future of extreme heatwaves. 00:45 How cold temperatures could starve tumoursA team of researchers have found that exposing mice to the cold could starve tumour cells of the blood glucose they need to thrive. They showed that the cold temperatures deprived the tumours of fuel by activating brown fat – a tissue that burns through glucose to keep body temperature up. The team also showed preliminary evidence of the effect occurring in one person with cancer, but say that more research is needed before this method can be considered for clinical use.Research article: Seki et al.08:59 Research HighlightsEvidence of the world's southernmost human outpost from before the Industrial Revolution, and how jumping up and down lets canoes surf their own waves.Research Highlight: Bones and weapons show just how far south pre-industrial humans gotResearch Highlight: How jumping up and down in a canoe propels it forwards11:24 The future of extreme heatwavesClimate scientists have long warned that extreme heat and extreme heatwaves will become more frequent as a result of climate change. But across the world these events are happening faster, and more furiously, than expected, and researchers are scrambling to dissect recent heatwaves to better understand what the world might have in store.News Feature: Extreme heatwaves: surprising lessons from the record warmth See acast.com/privacy for privacy and opt-out information.